Nicholas Argento MD, FACE
Maryland Endocrine and Diabetes, Columbia, Maryland
Dr. Argento is a senior clinical endocrinologist at the Maryland Endocrine and Diabetes Center in Columbia, Maryland, where he serves as the Diabetes Technology Director. 90% of his practice involves treating people with diabetes, about half of whom have T1D. He has lived with T1D since 1968. He testified to FDA representing the Endocrine Society (ES) as part of a successful effort to get direct dosing approval for the Dexcom G5 CGM, and represented ES in a key meeting with CMS that led to approval of CGM coverage for Medicare patients. He is part of a multi-organizational group working with CMS to update insulin pump policies. He co-authored multiple chapters in the ADA 2013 book, “Putting Your Patients on the Pump”, was primary investigator for 3 published retrospective studies on CGM use, co-authored a 2018 Diabetes Care update on real time and intermittently scanned CGM, and has written several other published commentaries on CGM use. He has presented on CGM and diabetes technology at multiple ADA, EASD and Diabetes Technology Society scientific sessions.